The Patent Finder

Multivalent Influenza Nanoparticle Vaccines

Novavax, Inc.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 2 of these applications claim priority to application 62/787,980, filed Jan 3, 2019. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 11,278,612Multivalent Influenza Nanoparticle Vaccines
In force
 · High confidence
Novavax, Inc.In force
High confidence
US 11,896,662Multivalent Influenza Nanoparticle Vaccines
In force
 · High confidence
Novavax, Inc.In force
High confidence
Application 18/403,182Multivalent Influenza Nanoparticle Vaccines
Abandoned
Abandoned Jul 24, 2025
Novavax, Inc.AbandonedAbandoned Jul 24, 2025
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Novavax, Inc..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited